3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Neoplasm Metastasis
10
Carcinoma, Non-Small-Cell Lung
10
Breast Neoplasms
9
Lung Neoplasms
5
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Neoplasms
4
Leukemia, Myeloid, Acute
4
Colorectal Neoplasms
4
Triple Negative Breast Neoplasms
3
Rectal Neoplasms
3
Melanoma
3
Leukemia
3
Glioblastoma
3
Cholangiocarcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Recurrence
2
Gliosarcoma
2
Glioma
2
Congenital Abnormalities
2
Colonic Neoplasms
2
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Thrombocythemia, Essential
1
Stomatitis
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pleural Effusion, Malignant
1
Pain
1
Interventions
Fulvestrant
3
Alpelisib
3
duvelisib
2
Cetuximab
2
volagidemab
1
talazoparib
1
ruxolitinib
1
parsaclisib
1
olaparib
1
obinutuzumab
1
lorlatinib
1
encorafenib
1
dapagliflozin
1
cobimetinib
1
chiauranib
1
binimetinib
1
avelumab
1
Vemurafenib
1
SF 1126
1
Rituximab
1
NVP-BKM120
1
Drug Therapy
1
CYH33
1
Aspirin
1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Hereditary Sensory and Autonomic Neuropathies
×
Drug Therapy
×
Clear all
NCT03386162
2022-11-28
SAFIR-PI3K
UNICANCER
Phase 2
Terminated
31 enrolled